Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
SARS-CoV-1/2 RdRp Inhibitor
SARS-CoV-IN-6 is a selective inhibitor of the RNA-dependent RNA polymerase (RdRp) of both SARS-CoV-1 and SARS-CoV-2, featuring an IC50 of 7.8 μM against SARS-CoV-2 RdRp. This compound effectively mitigates cytopathic effects in cells infected with SARS-CoV-1 and SARS-CoV-2 replicon-based single-round infectious particles (SRIPs). Additionally, it inhibits the expression of the SARS-CoV N protein, showing EC50 values of 0.12 µM for SARS-CoV-1 SRIPs and 1.47 µM for SARS-CoV-2 SRIPs. SARS-CoV-IN-6 is valuable for research focused on the antiviral mechanisms targeting coronavirus replication. -
SARS-CoV-2 Inhibitor
F8-S40 is a potent inhibitor of the SARS-CoV-2 main protease, demonstrating an IC50 of 10.88 μM. It exhibits significant antiviral activity, making it a valuable tool for researchers investigating COVID-19 therapies. This compound is suitable for studies focused on the inhibition of viral replication and the exploration of new therapeutic strategies against SAR-CoV-2. -
SARS-CoV-2 SP Inhibitor
SP Inhibitor 1 is a selective inhibitor of the SARS-CoV-2 spike protein, exhibiting an IC50 of 3.26 μM, while demonstrating minimal inhibition of Mpro and PLpro above 25 μM. This compound effectively inhibits SARS-CoV-2 replication in vitro at non-toxic concentrations ranging from 0.325 to 5.98 μM. SP Inhibitor 1 possesses significant cellular antiviral activity, making it a valuable tool for research applications focused on understanding and combating SARS-CoV-2. -
SARS-CoV-2 3CLpro Inhibitor
SARS-CoV-2 3CLpro-IN-20 is a covalent inhibitor of the SARS-CoV-2 3CL protease, with an IC50 of 0.43 μM and a Ki value of approximately 0.33 μM. This compound is essential for investigating the inhibition of the viral protease, which plays a crucial role in the replication of SARS-CoV-2. It serves as a valuable tool in research focused on antiviral drug discovery and the development of therapeutic strategies against COVID-19. -
SARS-CoV-2 Inhibitor
SARS-CoV-2 Mpro-IN-21 is a highly potent inhibitor of the SARS-CoV-2 Main Protease (MPro), targeting critical viral replication processes. This compound demonstrates significant antioxidant activity, with an IC50 of 0.36 mg/mL in the DPPH assay, indicating its potential in oxidative stress-related research. Furthermore, SARS-CoV-2 Mpro-IN-21 exhibits strong antibacterial activity against Klebsiella, with an IC50 of 1.19 mg/mL, making it a valuable tool for studies in viral and bacterial pathogenesis. -
SARS-CoV-2 Mpro Inhibitor
SARS-CoV-2 Mpro-IN-32 is a selective inhibitor of the SARS-CoV-2 main protease (Mpro), exhibiting an IC50 value of 230 nM. This compound effectively inhibits the replication of various SARS-CoV-2 variants in vitro, making it a valuable tool for studying the virus's biology and testing potential therapeutic strategies against COVID-19. Its specificity towards Mpro positions it as a significant candidate for further research in antiviral drug development. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-56 is a potent inhibitor of SARS-CoV-2, specifically targeting viral replication. This compound demonstrates significant antiviral activity, effectively inhibiting SARS-CoV-2 in Vero E6 cells with an IC50 value of 0.7 μM. It serves as a valuable reagent for research applications focused on understanding SARS-CoV-2 infection mechanisms and developing therapeutic strategies against COVID-19. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-22 is an inhibitor that targets the entry of SARS-CoV-2 pseudovirus into host cells, exhibiting an IC50 value of 16.96 µM. This compound is valuable for research applications focused on understanding viral entry mechanisms and developing therapeutic strategies against COVID-19. Its effective inhibition supports studies aimed at identifying potential antiviral agents and exploring host-pathogen interactions. -
SARS-CoV-2 3CLpro Inhibitor
SARS-CoV-2 3CLpro-IN-35 is an inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 of 0.15 μM. This compound demonstrates potent anti-SARS-CoV-2 activity and effectively inhibits the proliferation of bladder cancer cells while maintaining low cytotoxicity in fibroblasts. It is suitable for research applications focused on SARS-CoV-2 infection and bladder cancer treatment strategies. -
SARS-CoV-2 Mpro Inhibitor
CDD-1819 is a potent non-covalent, non-peptide inhibitor of the SARS-CoV-2 main protease (Mpro), exhibiting a Ki of 5 nM. This compound effectively inhibits mutant variants including ΔP168, A173V, and ΔP168/A173V Mpro. CDD-1819 serves as a valuable tool in research focused on COVID-19 therapeutic development and the mechanistic study of viral protease function. -
SARS-CoV-2 Mpro Inhibitor
NVP-EGT710 is an orally active, non-peptidomimetic covalent inhibitor of the SARS-CoV-2 main protease (Mpro). This compound demonstrates potent inhibitory activity against Mpro, making it a valuable tool for studying coronavirus infections. Its mechanism of action and specificity provide a promising avenue for research focused on antiviral therapeutics targeting SARS-CoV-2. -
SARS-CoV-2 Inhibitor
AT-9010 is a triphosphate active metabolite of AT-527 that serves as a potent inhibitor of the NiRAN enzyme, which is essential for the replication of SARS-CoV-2. This compound effectively inhibits the replication of the virus, making it a valuable tool for research into therapeutic strategies targeting COVID-19 and related coronaviruses. Its mechanism of action positions AT-9010 as a promising candidate for advancing our understanding of antiviral therapies. -
SARS-CoV-2 3CLpro Inhibitor
SARS-CoV-2 3CLpro-IN-16 is a covalent inhibitor targeting the SARS-CoV-2 3CL protease, exhibiting an IC50 of 2.124 μM. This compound selectively binds to the active site of the enzyme, forming a covalent bond with the cysteine residue at position 145. It is a valuable reagent for studying the inhibition of viral replication and may be utilized in research focused on developing antiviral therapies for COVID-19. -
SARS-CoV-2 Proteases Inhibitor
Methyl tanshinonate is a natural product derived from Salvia miltiorrhiza, targeting SARS-CoV-2 proteases. It exhibits potent inhibitory activity against the Mpro enzyme, with an IC50 value of 21.1 µM. This compound holds potential for research applications in the study of SARS-CoV-2 as well as diabetes-related investigations. -
SARS-CoV-2 Mpro Inhibitor
CDD-1733 is a potent non-covalent, non-peptide inhibitor of the SARS-CoV-2 main protease (Mpro), exhibiting an inhibitory constant (Ki) of 12 nM. This compound is effective against various Mpro variants, including ΔP168, A173V, and ΔP168/A173V. CDD-1733 is essential for research focused on antiviral drug development and the mechanistic study of SARS-CoV-2 pathogenesis. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-57, a potent inhibitor of SARS-CoV-2, exhibits an IC50 value of 80 nM, demonstrating significant antiviral activity. This compound has a high affinity for Sigma receptors, with Ki values of 13.6 nM for the Sigma-1 receptor and 14.4 nM for the Sigma-2 receptor. SARS-CoV-2-IN-57 is specifically designed for research applications focused on understanding and inhibiting SARS-CoV-2 viral mechanisms and interactions. -
SARS-CoV-2 Inhibitor
Z795161988 is a specific inhibitor of the SARS-CoV-2 Nsp14 N7-Methyltransferase, demonstrating an IC50 of 2.2 μM. This compound exhibits significant antiviral activity, making it a valuable tool for research focused on SARS-CoV-2 replication and pathogenesis. Its use in biochemical assays can facilitate the understanding of viral methylation processes and aid in the development of effective therapeutic strategies against COVID-19. -
SARS-CoV-2 3CLpro Inhibitor
3CPLro-IN-2 is a potent inhibitor of the SARS-CoV-2 3CLpro enzyme, demonstrating an IC50 of 1.55 μM and a Ki of 6.09 μM. The 3-chymotrypsin-like cysteine protease plays a crucial role in the viral replication process, making it a compelling target for therapeutic intervention in COVID-19 research. This compound has potential applications in the development of antiviral strategies aimed at mitigating SARS-CoV-2 infection. -
SARS-CoV-2 NPro Inhibitor
SARS-CoV-2-IN-17 is a potent inhibitor of the SARS-CoV-2 nucleocapsid protein (NPro). It demonstrates significant antiviral activity, with an EC50 of 2.18 μM. The compound binds to NPro with a low KD value of 7.82 μM, establishing it as a strong ligand for NPro. This reagent is valuable for research applications targeting SARS-CoV-2 and understanding its viral mechanisms. -
SARS-CoV-2 3CL Protease Inhibitors
MAC-5576 is a potent inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 of 81 nM. Additionally, it inhibits HAV 3C protease and thrombin with IC50 values of 0.5 μM and 13 μM, respectively. This compound serves as a valuable tool for research into antiviral therapies and protease inhibition mechanisms, particularly in the context of COVID-19. Its profile supports investigations into viral replication and potential therapeutic strategies. -
SARS-CoV Inhibitor
Isomitomycin A is a potent SARS-CoV-2 inhibitor that targets the hACE2 binding site of the viral spike glycoprotein. This compound demonstrates significant antiviral activity, making it a valuable tool for research into COVID-19 mechanisms and potential therapeutic interventions. Its application in studies related to SARS-CoV-2 reinforces its importance in the ongoing exploration of effective treatments for coronavirus infections. -
SARS-CoV-2 3CLpro Inhibitor
SARS-CoV-2 3CLpro-IN-17 is a selective inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 value of 0.322 μM. This compound targets the viral protease, disrupting the proteolytic processing of viral polyproteins, thereby inhibiting viral replication. It is a valuable tool for research focused on antiviral drug development and the study of SARS-CoV-2 biology. -
SARS-CoV-2 Inhibitor
SARS-CoV-2 3CLpro-IN-28 is a potent inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 of 0.018 μM. This compound effectively disrupts viral replication by targeting the enzymatic function essential for the processing of viral polyproteins. It is a valuable tool for research focused on antiviral strategies and the development of therapeutic agents against COVID-19. -
SARS-CoV-2 Inhibitor
ZINC475239213 is an inhibitor of the SARS-CoV-2 Nsp14 N7-Methyltransferase, exhibiting an IC50 of 20 μM. This compound demonstrates potential antiviral activity by disrupting viral replication mechanisms. It is suitable for research applications focused on COVID-19 and the development of therapeutic strategies against SARS-CoV-2. -
SARS-CoV-2 3Mpro Inhibitor
SARS-CoV-2 Mpro-IN-28 is a potent inhibitor of the SARS-CoV-2 main protease (Mpro), with an EC50 value of 24 μM. This compound is essential for studying the replication and pathogenesis of SARS-CoV-2. It plays a significant role in evaluating therapeutic strategies targeting viral protease activity and can facilitate the development of antiviral agents against COVID-19. -
SARS-CoV-2 Mpro Inhibitor
SARS-CoV-2 Mpro-IN-31 is a potent inhibitor of SARS-CoV-2 main protease (Mpro), exhibiting an IC50 of 11 nM. This compound also significantly inhibits the enzymatic activity of cysteine proteases cathepsin B and cathepsin L, with IC50 values of 24 nM and 1.8 nM, respectively. Its high specificity and efficacy make SARS-CoV-2 Mpro-IN-31 a valuable tool for research related to coronavirus pathology and enzyme regulation. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-95 is a potent inhibitor of the SARS-CoV-2 papain-like protease (PLpro) with an IC50 value of 0.39 μM. This compound demonstrates significant antiviral activity in mouse models of SARS-CoV-2 infection, making it a valuable tool for research on COVID-19 antiviral strategies and therapeutic development. -
SARS-CoV-2 Inhibitor
RU-0415529 is an orally bioavailable inhibitor targeting SARS-CoV-2 nonstructural protein 14 (NSP14), with an IC50 value of 356 nM. This compound effectively binds to the SAH-stabilized cap binding pocket, disrupting viral RNA methylation and subsequent viral replication. RU-0415529 demonstrates potent anti-infectious activity in mouse models, making it a valuable tool for research on SARS-CoV-2 virology and potential therapeutic applications. -
SARS-CoV-2 Mpro Inhibitor
NZ-804 is a potent inhibitor of the SARS-CoV-2 main protease (Mpro), exhibiting an IC50 of 8.9 nM. This compound effectively reduces SARS-CoV-2 replication in HeLa-hACE2 cells, with an EC50 of 14 nM. NZ-804 demonstrates broad-spectrum antiviral activity against various coronaviruses and has been shown to significantly diminish viral replication in mouse and hamster models, making it a valuable tool for research into COVID-19 and related viral infections. -
SARS-CoV-2 Papain-like Protease Inhibitor
Jun13296 is an orally active quinoline compound that functions as a potent inhibitor of the SARS-CoV-2 papain-like protease, with an IC50 of 0.13 µM and a Ki of 8.8 nM. This reagent demonstrates significant inhibitory activity against various SARS-CoV-2 variants, including those resistant to Nirmatrelvir. In in vivo studies, Jun13296 effectively reduces lung viral titers and mitigates lung tissue damage in models of SARS-CoV-2 infection, making it a valuable tool for COVID-19 research and therapeutic development. -
SARS-CoV-2 Inhibitor
MePT-S-N-Pme is an inhibitor of SARS-CoV-2 RNA-dependent RNA polymerase (RdRp). This compound exhibits significant antiviral activity, demonstrating reduced reporter activity with an IC50 of 7 μM in HEK 293 cells. Additionally, MePT-S-N-Pme shows a mild inhibitory effect on nucleotidyltransferase activity. Given its ability to significantly inhibit SARS-CoV-2 replication in vitro, MePT-S-N-Pme is a valuable tool for antiviral research and the development of therapeutic strategies against COVID-19. -
SARS-CoV-2 3CLpro Inhibitor
SARS-CoV-2 3CLpro-IN-18 is a covalent inhibitor targeting the SARS-CoV-2 3CL protease, with an IC50 of 0.478 μM. This compound exhibits antiviral activity against SARS-CoV-2 in Vero E6 cells, demonstrating an EC50 of 2.499 μM, while maintaining low cytotoxicity (CC50 > 200 μM). It serves as a valuable tool for research on SARS-CoV-2 inhibition and the development of therapeutic strategies against COVID-19. -
SARS-CoV-2 Inhibitor
SARS-CoV-2 3CLpro-IN-15 is a beta-nitrostyrene compound that serves as an inhibitor of the SARS-CoV-2 3C-like protease (3CLpro). This compound effectively inhibits viral replication and transcription, making it a valuable tool in the search for anti-COVID-19 lead compounds. Its mechanism of action highlights its potential in therapeutic applications against SARS-CoV-2 and related coronaviruses. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-59 is a non-peptide small molecule inhibitor targeting the main protease (Mpro) of SARS-CoV-2. This imidazoline derivative demonstrates significant interaction with critical residues in the Mpro active site, including Met 165, Gln 166, His 41, and Gln 189. SARS-CoV-2-IN-59 is a valuable tool for studying viral pathogenesis and potential therapeutic strategies against COVID-19. -
SARS-CoV-2 nsp13 Inhibitor
SARS-CoV-2 nsp13-IN-6 is a selective inhibitor of the non-structural protein 13 (nsp13) of SARS-CoV-2, demonstrating IC50 values of 27 μM and 33 μM for single-stranded DNA-dependent ATPase activity. This compound serves as a valuable tool for investigating the mechanisms of SARS-CoV-2 replication and offers potential applications in the development of therapeutic strategies against COVID-19. Its inhibition of nsp13 highlights its relevance in antiviral research aimed at disrupting viral replication. -
SARS-CoV-2 NSP14 Inhibitor
TDI-014925 is a potent inhibitor of the SARS-CoV-2 nonstructural protein 14 (NSP14) with an IC50 of 0.2 nM. This compound exhibits significant antiviral activity and demonstrates excellent microsomal stability without CYP inhibition. TDI-014925 is suitable for research applications related to COVID-19 and the biochemical characterization of viral methyltransferase functions. -
SARS-CoV Inhibitor
NK007 is a potent inhibitor of SARS-CoV-2, demonstrating an EC50 value of 30 nM. This compound disrupts viral replication, making it a valuable tool for studying SARS-CoV-2 infection mechanisms and evaluating potential therapeutic strategies against COVID-19. Its efficacy in inhibiting viral activity positions NK007 as a significant reagent for research in virology and infectious disease. -
SARS-CoV-2 Mpro Inhibitor
UAWJ-247 is a potent and reversible inhibitor of the SARS-CoV-2 main protease (Mpro), exhibiting an IC50 value of 0.042 μM and a Ki of 0.035 μM. This compound demonstrates significant antiviral activity, making it a valuable tool for research into therapeutic strategies against COVID-19. Its efficacy in inhibiting virus replication positions UAWJ-247 as a relevant agent for studies focused on SARS-CoV-2 drug development. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-38 is an inhibitor targeting the SARS-CoV-2 virus, demonstrating significant potential in antiviral research. This compound exhibits favorable oral bioavailability in murine models, achieving a bioavailability rate of 39.75%. It is relevant for studies focused on the development of therapeutics aimed at combating COVID-19 and related viral infections. -
SARS-CoV nsp14 Inhibitor
SARS-CoV-IN-4 is a potent inhibitor of the SARS-CoV nsp14 N7-methyltransferase, with an IC50 of 0.6 μM. This compound offers specificity in targeting the N7-methyltransferase activity, making it a valuable tool for studying viral RNA modification processes. SARS-CoV-IN-4 is relevant for research applications related to antiviral drug discovery and the mechanistic understanding of SARS-CoV replication and pathogenesis. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-44 is a potent inhibitor targeting SARS-CoV-2, effectively blocking viral replication with an EC50 of 0.6 μM. The compound demonstrates minimal cytotoxicity in Calu-3 cells, making it suitable for antiviral research. Its profile supports investigations into therapeutic strategies against SARS-CoV-2 infection. -
SARS-CoV-2 Inhibitor
Crepidiaside B is a natural compound derived from Cichorium intybus that functions as an inhibitor of the SARS-CoV-2 spike glycoprotein. This compound exhibits antiviral activity and is utilized in research studies focused on coronavirus disease 2019 (COVID-19) and the mechanisms of viral entry into host cells. Its potential therapeutic implications make it a valuable tool in the ongoing efforts to combat SARS-CoV-2. -
SARS-CoV-2 Inhibitor
CMX990 is an inhibitor of the SARS-CoV-2 3CL protease, demonstrating potent antiviral activity with EC90 values of 9.6 nM in human bronchial epithelial cells and 101 nM in HeLa-ACE2 cells. This reagent exhibits favorable absorption, distribution, metabolism, and excretion (ADME) properties, making it suitable for research in virology and drug development targeting coronavirus infections. -
SARS-CoV-2 Mpro Inhibitor
SARS-CoV-2 Mpro-IN-12 is an inhibitor of the SARS-CoV-2 main protease (Mpro), a critical enzyme in the viral life cycle. This compound demonstrates potent antiviral activity, making it a valuable tool for studying viral replication mechanisms and developing therapeutic strategies against COVID-19. Its specificity for Mpro allows for focused research on the inhibition of SARS-CoV-2 and the evaluation of potential antiviral agents. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-20 is a targeted inhibitor of SARS-CoV-2 with an effective concentration (EC50) of 6.5 μM. This compound demonstrates significant antiviral activity, making it a valuable tool for research applications focused on infectious diseases, particularly COVID-19. Its inhibitory properties enable studies on viral replication and therapeutic interventions. -
SARS-CoV-2 3CLpro Inhibitor
SARS-CoV-2-IN-12 is a potent inhibitor of the SARS-CoV-2 3C-like protease (3CLpro), demonstrating a Ki value of 32.1 pM. This compound effectively prevents viral replication, making it a valuable tool for research applications focused on COVID-19. Its high potency and specificity aid in investigations aimed at understanding and developing therapeutic strategies against SARS-CoV-2. -
SARS-CoV-2 Inhibitor
SARS-CoV-2 Mpro-IN-9 is a nonpeptidic, noncovalent inhibitor targeting the main protease (Mpro) of SARS-CoV-2, exhibiting an IC50 of 0.085 μM. This compound demonstrates effective inhibition of viral replication in SARS-CoV-2-infected Vero E6 cells, with an EC50 of 1.10 μM, while showing low cytotoxicity (CC50 > 50 μM). SARS-CoV-2 Mpro-IN-9 is significant for research applications focused on antiviral strategies against COVID-19 and the development of therapeutic agents. -
SARS-CoV-2 NSP14 MTase Inhibitor
NSC111552 is a selective inhibitor of the SARS-CoV-2 NSP14 methyltransferase (MTase), demonstrating significant potency. It effectively disrupts FL-NAH binding to the NSP14 MTase with an IC50 value of 5.1 μM. This compound is valuable for research into SARS-CoV-2 replication processes and the development of antiviral therapies targeting the viral MTase activity. -
SARS-CoV-2 3CLpro Inhibitor
SARS-CoV-2 3CLpro-IN-32 is a highly potent inhibitor of the SARS-CoV-2 3CLpro enzyme, characterized by an IC50 value of 0.109 μM. In addition to its inhibitory effects on SARS-CoV-2, this compound demonstrates antiviral activity against the coronavirus HCoV-OC43, with an EC50 of 1.99 μM. It is a valuable tool for researchers studying viral replication and therapeutic strategies against coronavirus infections. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-84 is a selective inhibitor of the SARS-CoV-2 3CL protease (3CL Pro), with an IC50 value of 369.5 nM. This compound demonstrates potent antiviral activity against SARS-CoV-2 and is valuable for research applications focused on developing therapeutic strategies for COVID-19. Its mechanism of action provides insights into viral replication processes, making it an essential tool for virology studies and drug discovery efforts targeting SARS-CoV-2.
